182 related articles for article (PubMed ID: 23360557)
1. High efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors.
Sommariva M; de Cesare M; Meini A; Cataldo A; Zaffaroni N; Tagliabue E; Balsari A
J Transl Med; 2013 Jan; 11():25. PubMed ID: 23360557
[TBL] [Abstract][Full Text] [Related]
2. Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN.
De Cesare M; Sfondrini L; Campiglio M; Sommariva M; Bianchi F; Perego P; van Rooijen N; Supino R; Rumio C; Zunino F; Pratesi G; Tagliabue E; Balsari A
J Immunother; 2010 Jan; 33(1):8-15. PubMed ID: 19952960
[TBL] [Abstract][Full Text] [Related]
3. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
[TBL] [Abstract][Full Text] [Related]
4. TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects.
Sommariva M; De Cecco L; De Cesare M; Sfondrini L; Ménard S; Melani C; Delia D; Zaffaroni N; Pratesi G; Uva V; Tagliabue E; Balsari A
Cancer Res; 2011 Oct; 71(20):6382-90. PubMed ID: 21878529
[TBL] [Abstract][Full Text] [Related]
5. CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.
Hiramatsu K; Serada S; Kobiyama K; Nakagawa S; Morimoto A; Matsuzaki S; Ueda Y; Fujimoto M; Yoshino K; Ishii KJ; Enomoto T; Kimura T; Naka T
Cancer Sci; 2015 Oct; 106(10):1474-8. PubMed ID: 26498112
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft.
Pratesi G; Petrangolini G; Tortoreto M; Addis A; Belluco S; Rossini A; Selleri S; Rumio C; Menard S; Balsari A
Cancer Res; 2005 Jul; 65(14):6388-93. PubMed ID: 16024642
[TBL] [Abstract][Full Text] [Related]
7. Phosphorothioate modification of the TLR9 ligand CpG ODN inhibits poly(I:C)-induced apoptosis of hepatocellular carcinoma by entry blockade.
Zhang Y; Lin A; Sui Q; Zhang C; Tian Z; Zhang J
Cancer Lett; 2014 Dec; 355(1):76-84. PubMed ID: 25224571
[TBL] [Abstract][Full Text] [Related]
8. Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer.
Chuang CM; Monie A; Wu A; Mao CP; Hung CF
Hum Gene Ther; 2009 Apr; 20(4):303-13. PubMed ID: 19272013
[TBL] [Abstract][Full Text] [Related]
9. CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma.
Wang XS; Sheng Z; Ruan YB; Guang Y; Yang ML
World J Gastroenterol; 2005 Feb; 11(8):1220-4. PubMed ID: 15754409
[TBL] [Abstract][Full Text] [Related]
10. The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models.
Clémenson C; Jouannot E; Merino-Trigo A; Rubin-Carrez C; Deutsch E
Invest New Drugs; 2013 Apr; 31(2):273-84. PubMed ID: 22810221
[TBL] [Abstract][Full Text] [Related]
11. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma.
Wooldridge JE; Ballas Z; Krieg AM; Weiner GJ
Blood; 1997 Apr; 89(8):2994-8. PubMed ID: 9108420
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the efficacy of a bevacizumab-cetuximab-cisplatin regimen in treating head and neck squamous cell carcinoma in mice.
Wang Y; Dong L; Bi Q; Li X; Wu D; Ge X; Zhang X; Fu J; Zhang C; Wang C; Li S
Target Oncol; 2010 Dec; 5(4):237-43. PubMed ID: 21086056
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.
Oliva P; Decio A; Castiglioni V; Bassi A; Pesenti E; Cesca M; Scanziani E; Belotti D; Giavazzi R
Br J Cancer; 2012 Jul; 107(2):360-9. PubMed ID: 22713663
[TBL] [Abstract][Full Text] [Related]
14. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
Roda JM; Parihar R; Carson WE
J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
[TBL] [Abstract][Full Text] [Related]
15. CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts.
De Cesare M; Sfondrini L; Pennati M; De Marco C; Motta V; Tagliabue E; Deraco M; Balsari A; Zaffaroni N
J Transl Med; 2016 Jan; 14():25. PubMed ID: 26810896
[TBL] [Abstract][Full Text] [Related]
16. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
17. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
18. CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors.
Mason KA; Neal R; Hunter N; Ariga H; Ang K; Milas L
Radiother Oncol; 2006 Aug; 80(2):192-8. PubMed ID: 16905212
[TBL] [Abstract][Full Text] [Related]
19. Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy.
De Cesare M; Calcaterra C; Pratesi G; Gatti L; Zunino F; Mènard S; Balsari A
Clin Cancer Res; 2008 Sep; 14(17):5512-8. PubMed ID: 18765543
[TBL] [Abstract][Full Text] [Related]
20. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.
Gong JH; Liu XJ; Li Y; Zhen YS
Cancer Chemother Pharmacol; 2012 May; 69(5):1323-32. PubMed ID: 22311160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
